This systematic review and meta-analysis compared the efficacy and toxicity of dexamethasone (DEX) versus prednisone (PRED) for induction therapy in childhood acute lymphoblastic leukemia (ALL). We searched biomedical literature databases and conference proceedings for randomized controlled trials comparing DEX and PRED during induction therapy for childhood ALL. A total of eight studies were eligible for inclusion in this meta-analysis. DEX, in comparison with PRED, reduced events (that is, death from any cause, refractory or relapsed leukemia, or second malignancy; risk ratio (RR) 0.80; 95% confidence interval (CI), 0.68-0.94) and central nervous system relapse (RR 0.53; 95% CI, 0.44-0.65), but did not alter bone marrow relapse (RR 0.90; 95% CI, 0.69-1.18) or overall mortality (RR 0.91; 95% CI, 0.76-1.09). Patients receiving DEX had a higher risk of mortality during induction (RR 2.31; 95% CI, 1.46-3.66), neuro-psychiatric adverse events (RR 4.55; 95% CI, 2.45-8.46) and myopathy (RR 7.05; 95% CI, 3.00-16.58). There was no statistically significant difference in the risk of osteonecrosis, sepsis, fungal infection, diabetes or pancreatitis. DEX in induction therapy for children with ALL is more efficacious than PRED. However, DEX is also associated with more toxicity, and currently it remains unclear whether shortterm superiority of DEX will also result in better overall survival.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, and currently more than 80% of children with ALL are cured. 1 The backbone of contemporary multiagent chemotherapeutic regimens is formed by four elements: induction, central nervous system (CNS)-directed treatment and consolidation, reinduction and maintenance. 2 The goal of induction therapy is to induce remission and to restore normal hematopoiesis. Induction therapy typically contains at least three systemic drugs (that is, a corticosteroid, vincristine and L-asparaginase) and intrathecal therapy. 3 The addition of an anthracycline as a fourth drug is variable. In some protocols all patients receive an anthracycline; 4 in other protocols it is reserved for high-risk cases. 5 The majority of clinical trials in the 1980s and 1990s had used prednisone or prednisolone (PRED) for remission induction therapy in childhood ALL. 2 However, two randomized trials, namely CCG-1922 and MRC ALL-97/99, demonstrated that the substitution of PRED by dexamethasone (DEX) could decrease the risk of bone marrow and CNS relapse. 6, 7 It is, however, important to state that corticosteroid randomization in those two trials was not limited to induction therapy but also encompassed other treatment phases including maintenance therapy. In contrast, a Japanese study (TCCSG L95-14) did not confirm the advantage of using DEX when PRED was used at a higher dose. 8 It is difficult to compare the current evidence in the literature because of substantial differences between trials in terms of study design. First, different relative doses of PRED and DEX were used in those trials. In CCG-1922 and MRC ALL-97/99, for example, PRED and DEX were given in doses corresponding to PRED/DEX dose ratios between 6:1 and 7:1. The Japanese study, on the contrary, modified the corticosteroid doses in such a way that the PRED/DEX dose ratio exceeded 7:1. A more recent European trial (EORTC 58951) even used a dose ratio of 10:1. 9 Consequently, the absolute drug doses of PRED and DEX varied between the trials. Further, heterogeneity in regard to induction regimen (three-or four-drug induction) and/or study population (age, leukemia subtypes, risk groups) further complicates the interpretation of the currently available data in the literature.
A recently published narrative review discussed the optimal use of corticosteroids in pediatric ALL. 10 However, thus far, no study has quantitatively synthesized the evidence regarding the optimal use of corticosteroids during induction therapy, or has formally examined how this evidence varies depending on the sources of heterogeneity described previously, including PRED/ DEX dose ratio and/or therapy/population characteristics. To arrive at comprehensive estimates of efficacy and toxicity from all randomized trials conducted to date, we undertook a systematic literature review and meta-analysis of all randomized controlled trials comparing DEX versus PRED during induction chemotherapy in childhood ALL. Our objective was to compare the efficacy and toxicity of DEX versus PRED during induction chemotherapy in childhood ALL.
Materials and methods
We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement for reporting our results. 11 The abbreviation PRED encompasses both prednisone and prednisolone. Prednisolone is the active metabolite of prednisone. It has the same glucocorticoid and mineralocorticoid potency, and is typically given in an equivalent dose of 1:1.
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Data sources and searches
We performed an electronic search of OVID MEDLINE (from 1950 to September 2010), EMBASE (from 1980 to September 2010) and The Cochrane Central Register of Controlled Trials (CENTRAL; until the third quarter of 2010; detailed search strategy provided in Supplementary Data A). We also searched relevant references and conference proceedings from 2007 to 2010 using the Web of Science and Scopus databases.
Study selection
We included all randomized controlled trials comparing DEX with PRED during induction therapy in childhood ALL that reported at least one outcome of interest (see below; data extraction). All children and adolescents with the first diagnosis of ALL were included in this review. There was no restriction by study site/country, quality of the study or follow-up period. Further, there was no restriction by dose, frequency, method of drug administration, length of induction therapy or concurrent chemotherapy.
One review author (OT) inspected the abstract of each reference identified by the search and applied the inclusion criteria. For possibly relevant articles, the full article was obtained and reviewed by two authors (OT and SPK) independently. Final inclusion of studies was determined by agreement of both reviewers and involvement of a third author in cases of discrepancy. Agreement between reviewers was evaluated by using a kappa statistic. 13 Data extraction and quality assessment Two review authors (OT and SPK) independently extracted data from included trials. Data extraction was performed using a standardized data collection form. When missing data were encountered, the corresponding authors were contacted to retrieve these data.
The primary outcome measures were (1) event rate; event was defined as death from any cause, refractory or relapsed leukemia, or second malignancy; 7, 8, 14 (2) relapse rate, specifically: (a) any CNS-relapse (if not reported as such, isolated CNS relapse (first choice) or extramedullary relapse (second choice) were analyzed), (b) isolated bone marrow relapse (if not reported as such, non-CNS relapse was analyzed), (c) isolated testicular relapse or (d) combined relapse (any combination of CNS, bone marrow or testicular relapse); and (3) mortality rate. The observation time point was defined by each study differently but varied between 5 and 8 years.
The secondary outcome measures were (1) death during induction therapy (defined as within 60 days after treatment initiation); (2) osteonecrosis (at any time); (3) patients who came off study following corticosteroid randomization; (4) sepsis; (5) fungal infection; (6) diabetes; (7) neuro-psychiatric events; (8) pancreatitis; and (9) myopathy.
We assumed equal group sizes of randomized groups if not reported in detail by the authors, which was the case for three conference abstracts. [14] [15] [16] Data were extracted as proportions if results were only reported as probability of events, relapse or mortality, and if the number of events was not explicitly provided.
To assess methodological quality and risk of bias, included articles were examined for: (1) sequence generation; (2) allocation concealment; (3) blinding; (4) incomplete outcome data, and (5) intention-to-treat analysis (definitions/criteria were derived from the Cochrane Handbook for Systematic Reviews of Interventions).
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Data synthesis and analysis
Outcomes with at least two eligible studies were synthesized; synthesis was performed using Review Manager (Version 5.0, The Cochrane Collaboration 2008, The Nordic Cochrane Centre, Copenhagen, Denmark). We performed intention-to-treat analysis and determined risk ratios (RR) with 95% confidence intervals (CI) for dichotomous data (Mantel-Haenszel's method). P-valueso0.05 were considered statistically significant.
We performed subgroup analyses for all outcomes to investigate the effect of the PRED/DEX dose ratio (o7 versus X7). The cutoff of seven was chosen because this is the typical conversion between DEX and PRED as reported in the literature (that is, 1 mg DEX is approximately equivalent to 7 mg PRED). 12, 18, 19 We also planned subgroup analyses to investigate the effects of age, gender and immunophenotype. Subgroup analysis required a minimum of two studies for each group. We further explored our data with sensitivity analyses. We evaluated the impact of the following: (1) prednisone versus prednisolone; (2) three-drug versus four-drug induction; and (3) corticosteroid randomization restricted to induction versus corticosteroid randomization in induction plus other protocol phases.
Because we anticipated heterogeneity between studies, a random-effects model was used for all analyses. Statistical heterogeneity was initially inspected graphically (forest plot) and assessed by calculating tests of heterogeneity using the Cochran Q-test (w 2 test). We quantified the degree of heterogeneity using the I 2 statistic. 20 Publication bias was investigated using a funnel plot in which the standard error of the effect estimate of each study was plotted against the estimate. 21 An asymmetric plot suggested possible publication bias. Optimal corticosteroid use in childhood leukemia O Teuffel et al 23 full articles were retrieved. Of these, eight studies satisfied eligibility criteria and were included in the metaanalysis. [6] [7] [8] [9] [14] [15] [16] 22 The reviewers had perfect agreement on articles for inclusion, with a k statistic of 1.0. The reasons for excluding 15 articles are shown in Figure 1 . [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Characteristics of included studies are presented in Table 1 (patients in trial ALL-BFM 2000 were also part of the larger multi-national AIEOP-BFM ALL 2000). Three-drug induction was reported for three trials (all patients: CALGB7111, CCG-1922; only standard-risk patients: MRC ALL-97/99); four-drug induction was reported for five trials (all patients: TCCSG L95-14, (AIEOP-)BFM ALL 2000, EORTC 58951; only high-risk patients: MRC ALL-97/99, COG AALL0232). Four trials used prednisone (CALGB7111, CCG-1922, (AIEOP)-BFM ALL 2000, COG AALL0232), whereas three trials used prednisolone (TCCSG L95-14, EORTC 58951, MRC ALL-97/99).
Risk of bias assessment has been hampered by the fact that four of the eight studies, so far, have only published preliminary data in form of conference abstracts (AIEOP-BFM ALL 2000 and ALL-BFM 2000, respectively; COG AALL0232, EORTC 58951). Considering all trials, allocation generation and concealment information were available for one and two trials, respectively. 7, 9 Blinding status was not reported by any study. Withdrawal information could be retrieved from four of the eight, [6] [7] [8] 22 and intention-to-treat analysis was reported for three trials 6, 8, 14, 16 (Supplementary Data B). The synthesis of event rates encompassed 4176 (DEX) and 4204 (PRED) patients. When weighted data from five studies were synthesized, DEX reduced the event rate as compared with PRED (RR 0.80; 95% CI, 0.68-0.94; P ¼ 0.005). There was significant heterogeneity between these studies (I 2 ¼ 60%; P ¼ 0.04), indicating differences in the effect of DEX relative to PRED between included trials. Stratified analysis (PRED/DEX dose ratios o7 versus X7) was performed to explore the heterogeneity. Subsequently, superiority of the DEX group was observed only in studies with a PRED/DEX dose ratio o7 (ratio o7: RR 0.73; 95% CI, 0.66-0.81; Po0.001; in contrast to ratio X7: RR 1.01; 95% CI, 0.84-1.22; P ¼ 0.88; Figure 2 and Table 2 ).
A total of six studies provided information to synthesize data related to CNS and bone marrow relapse rates (8873 patients). DEX, as compared with PRED, decreased the risk of CNS relapse in children with ALL (RR 0.53; 95% CI, 0.44-0.65; Po0.001; I 2 ¼ 0%; Figure 3 and Table 2 ). On the contrary, there was no effect of DEX on the risk of bone marrow relapse (RR 0.90; 95% CI, 0.69-1.18; P ¼ 0.45). Qualitatively, there appeared to be superiority for DEX in studies with PRED/DEX dose ratios o7 and superiority for PRED in studies using ratios X7 (both non-significant; Table 2 and Supplementary Data C). No significant difference between DEX and PRED was identified in terms of overall mortality (three studies) 6, 7, 22 or testicular relapse (two studies) 6, 8 ( Table 2) . Only one study provided data regarding combined relapse.
8 Data F) , sepsis, fungal infection, Abbreviations: DEX, dexamethasone; HR, high-risk patients; ID, identity; NA, not applicable (also refers to studies that evaluated acute toxicity); NR, not reported; PRED, prednisone/prednisolone. a Last update 10 years after study initiation (7 years after study completion). For only two studies (Mö ricke, Mattano), toxicity (osteonecrosis) was a primary objective. In all other studies, side effects were reported as a secondary objective.
Optimal corticosteroid use in childhood leukemia O Teuffel et al diabetes or pancreatitis. There were not enough studies available to perform stratified analyses in regard to the PRED/ DEX dose ratio. There were also not enough data available to perform subgroup analyses to investigate the effects of age, gender and immunophenotype for either efficacy or toxicity. Extensive sensitivity analyses on all outcome measures were performed to assess the robustness of our findings. Corticosteroid choice (prednisone versus prednisolone), induction intensity (threedrug versus four-drug induction) and length of randomization (corticosteroid randomization restricted to induction versus corticosteroid randomization in induction plus other protocol phases) did not significantly impact on the results (Supplementary Data G and H). Abbreviations: CI, confidence interval; CNS, central nervous system; DEX, dexamethasone; PRED, prednisone/prednisolone. Risk ratios o1 indicate superiority of dexamethasone. Note: Subgroup analysis data (dose ratio) are only displayed if there were at least two studies per strata.
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As all analyses included less than 10 studies each, tests for funnel plot asymmetry were not performed.
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Discussion
There is uncertainty in regard to the optimal choice of corticosteroids during induction therapy for childhood ALL. 10 Our meta-analysis is important because it is the first study, to our knowledge, to quantitatively synthesize the evidence comparing efficacy and toxicity of DEX versus PRED. Our study suggests that DEX is more efficacious than PRED when given during induction therapy. However, DEX is also associated with more toxicity, and currently it remains unclear whether short-term superiority of DEX will translate to superior overall survival with longer follow-up.
We anticipated similar effects on event rates of the included trials before initiating data synthesis. Accordingly, we pooled the weighted estimates of each study. However, initial assessment revealed substantial heterogeneity between the studies. Our analysis suggests that this heterogeneity is largely related to different PRED/DEX dose ratios applied in the different trials, with greater efficacy with larger relative DEX dosing, indicating that the presumed equivalent anti-leukemic activity for PRED/ DEX is not a 6:1-7:1 dose ratio, but is higher, as some in vitro experiments suggest. 38 Although our study is able to provide further information in regard to relative corticosteroid doses, the impact of absolute doses on our findings remains unknown. Meta-regression would have been an optimal approach to further explore a dose-effect function of PRED and DEX; however, too few studies were available to consider such an analysis.
Both CCG-1922 and MRC ALL-97/99 were associated with the largest effects of DEX in regard to the event rate, and both trials randomized DEX versus PRED throughout their treatment protocol. Although assessed in sensitivity analyses, we cannot exclude that prolonged exposure to DEX, especially during maintenance therapy, may impact on event-free survival rates. However, AIEOP-BFM ALL 2000, which limited the corticosteroid randomization to induction, was also associated with a significant benefit for DEX, indicating a substantial impact of the corticosteroid choice during remission induction on treatment outcome.
Improved event-free survival did not result in improved overall survival. There are three possible explanations for this: (1) higher salvage rates of children in the PRED group after events as compared with patients who received DEX, (2) lack of power to demonstrate an effect on overall survival or (3) insufficient follow-up time. Further research, including repeating this systematic review after current studies will have matured and provided longer follow-up, would determine the long-term impact of initial corticosteroid randomization on survival. On the contrary, there was clear evidence that DEX was protective against CNS relapse, with fewer CNS relapses observed with DEX at all PRED/DEX ratios and absolute doses. This finding supports existing literature reporting better CNS penetration of DEX as compared with PRED. 39 A possible interaction (for example, synergy effect) with other modes of CNS prophylaxis, such as intrathecal therapy or systemic highdose methotrexate, may also impact on the effect size of DEX; however, there were too few studies to formally address this issue. Data interpretation in regard to bone marrow relapses is less clear. Although not statistically significant, there was a trend to superiority of PRED over DEX if the dose ratio exceeds 7 whereas DEX appeared superior for studies with dose ratios below 7. We found that the PRED/DEX ratio explained heterogeneity in regards to corticosteroid efficacy, and thus, we suggest that the relative drug dosing of PRED and DEX has an important impact on clinical outcomes. It is possible that the equivalent anti-leukemic activity for PRED/DEX may differ between CNS, bone marrow and testes.
Overall, there was a trend for increased toxicity in patients who received DEX. Moreover, patients who received DEX were at significant higher risk to come off study after randomization 
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O Teuffel et al because of adverse events. However, there was substantial heterogeneity depending on the outcome of interest. The risk, for example, to develop neuro-psychiatric side effects was more than fourfold increased in patients receiving DEX. Better CNS penetration of DEX as compared with PRED may reasonably explain this observation. 39 In contrast, the incidence of osteonecrosis did not significantly differ between the two corticosteroids. However, conclusions related to the impact of DEX on osteonecrosis may be limited in this review. First, accurate ascertainment of osteonecrosis was likely limited in older studies. Thus, we cannot exclude that underreporting of certain late effects, which could include osteonecrosis, might impact on the validity of our findings. Second, osteonecrosis occurs very rarely in patients younger than 10 years, 6, 8 and unfortunately, we could not perform subgroup analysis to assess the role of age in influencing the impact of steroid formulation on osteonecrosis. Confounders such as chemotherapy intensity (for example, for high-risk patients) may further influence the incidence of osteonecrosis. 15 The effect of the PRED/DEX ratio on adverse events was difficult to examine because of the limited number of studies. Finally, it is important to state that the inferior toxicity profile of DEXFwhich is, however, accompanied by lower relapse ratesFshould be weighed against the severe side effects associated with a possible salvage therapy in patients with relapse who received PRED during their first course of treatment.
Our systematic review has two important limitations. First, meta-regression would have been an optimal approach to better examine potential confounders at the study level (that is, randomization duration, CNS regimen, and so on), and to further analyze the dose-response relationship between PRED/ DEX dosing and clinical outcomes. However, there were too few studies to consider such an analysis. Second, a metaanalysis of individual patient data would have been a way to better adjust for patient-level covariates, such as patient age or leukemia subtype. However, as long as the steroid randomization stratified for these factors, individual patient-level metaanalysis may not offer substantial advantages but would be greatly onerous in terms of costs and time. To our knowledge our quantitative analysis of data from eight trials comprising more than 8000 prospectively assigned patients provides the most complete estimate of corticosteroid comparison available.
Our meta-analysis suggests that DEX is more efficacious and more toxic than PRED when given during induction therapy in childhood ALL. However, further analysis could better define whether these effects are restricted to specific subpopulations. Thus, we suggest that future research should consider an individual patient meta-analysis to better understand the impact of age, gender and leukemia characteristics on clinical outcomes in patients who receive PRED or DEX during induction therapy. However, such an analysis should be performed when current studies will have matured after longer follow-up. This will facilitate the evaluation whether higher event-free survival rates of DEX will result in better long term overall survival. Finally, future research should further evaluate the benefit of DEX in induction only, with PRED used for the remainder of treatment because of the potential improvement in the toxicity profile of the therapy. Such research should also carefully consider the role of different dose schedules for DEX and its possible impact on different side effects.
